Dianthus Therapeutics (DNTH) Net Income towards Common Stockholders (2017 - 2025)

Dianthus Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$162.9 million for Q3 2025.

• In Q3 2025, Net Income towards Common Stockholders fell 118.65% year-over-year to -$162.9 million; the TTM figure through Dec 2025 stood at -$256.8 million (down 8.55% YoY), while the FY2024 annual figure was -$266.1 million, down 59.48% from the prior year.
• Net Income towards Common Stockholders for Q3 2025 stood at -$162.9 million, down from -$50.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$7.1 million in Q1 2023, with the low at -$162.9 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$32.9 million (2022), against an average of -$42.4 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 81.67% in 2023, then tumbled 872.48% in 2024.
• Dianthus Therapeutics' Net Income towards Common Stockholders stood at -$24.5 million in 2021, then soared by 58.94% to -$10.1 million in 2022, then declined by 4.57% to -$10.5 million in 2023, then tumbled by 167.56% to -$28.1 million in 2024, then plunged by 479.02% to -$162.9 million in 2025.
• Business Quant data shows DNTH's Net Income towards Common Stockholders at -$162.9 million in Q3 2025, -$50.6 million in Q2 2025, and -$43.4 million in Q1 2025.